Smith & Nephew plc

Fundamentals8.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Robust margins
  • Healthy cashflow
  • Significant intangibles

AI
AI Summary

6.0

Smith & Nephew has shifted from a defensive cash-generator into a higher‑growth, innovation-led orthopaedics and wound‑care play via M&A and new product launches, but the investment thesis now hinges on successful commercial rollouts and durable margin conversion rather than steady consumables cash flow. Monitor quarterly organic revenue mix in RCR/robotics/wound care, gross-to-EBITDA conversion and working‑capital trends (and whether price reclaims the mid‑$36s); failure to execute would likely trigger impairments, compress the multiple and stress leverage.

Innovation
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • Robust margins
  • Healthy cashflow
  • Significant intangibles

SNN delivers strong margins and cash generation but is tempered by nearly 1:1 leverage, large intangibles and working-capital exposure that limit its valuation upside.

Margins
Leverage

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Trading at lows
  • Resistance mid‑$36s

Over the last month SNN has been in a clear downtrend, falling about 11.6% from $36.13 to $31.94 (≈13–14% from the late‑February peak), trading at period lows with support near $31.9–$32.0 and resistance in the mid‑$36s—risk of further downside until a sustained reclaim of the mid‑36s occurs.

bearish
watch
Support Level: $31.90–$32.00
Resistance Level: $36.70–$36.90

~11.6% decline last month (36.13 → 31.94) and ~13–14% drop from the late‑Feb peak

Sentiment & News

7.0

Key News Insights:

  • Revenue & profit
  • Margin expansion
  • New product launches

Smith & Nephew delivered stronger-than-expected fiscal 2025 results with revenue and profit growth, margin expansion and rising free cash flow, backed by new product launches and strategic U.S. distribution deals amid some investor repositioning and valuation scrutiny.

growth
valuation

Positive operational momentum and commercial deals should support near-term stock sentiment, though the reduced institutional stake and valuation questions could cap upside